The field of hepatitis C disease management is in the midst of dramatic change. This series provides overviews, research updates, and more.

thumbnail image for headlineWhat Are the Hepatitis C Genotypes?

thumbnail image for headlineReal-World Hepatitis C Cure Rates Higher With 2 Direct Acting Agents

thumbnail image for headlineHepatitis C Resources, Services and Information

thumbnail image for headlineHCV Medications by Drug Class


This Week in HIV Research: Reducing Cardiovascular Risk; and Monitoring Renal Function With PrEP

NIH's Dr. Dieffenbach Discusses Launch of HIV Vaccine Clinical Trial in South Africa

High Hepatitis C Cure Rates With Harvoni and Viekira Pak in Veterans With Genotype 1

Curing Hepatitis C Lowers but Does Not Eliminate Risk of Liver Cancer

Treatment With ABT-493/ABT-530 Cures 99% of Patients With Hepatitis C Genotype 2

MK3, a One-Pill Triple Direct-Acting Antiviral, Effective for Hepatitis C Genotypes 1, 2, and 3

Coordinated Care in Poor Neighborhoods Overcomes Some Barriers to Hepatitis C Treatment

Only 49% Transmission Rate Observed in Kidney Transplants From HCV-Positive Donors, but Lower Graft and Survival Overall

Hepatitis C Cure Rates Similar Among Specialists, Primary Care Providers, Nurses

Hepatitis C Cure Rate 93% With Elbasvir/Grazoprevir for Genotype 1 or 4

Top 10 HIV Clinical Developments of 2016

Use of Syringe Services Programs Increases, but Access Must Improve for Greater HIV Prevention

CDC Publishes 2015 HIV Surveillance Report

First New HIV Vaccine Efficacy Study in Seven Years Has Begun

WHO Issues Guidelines for HIV Self-Testing, Partner Notification